A hard pill to swallow: A qualitative study of women's experiences of adjuvant endocrine therapy for breast cancer

BMJ Open

Volumn 4, Issue 6, 2014, Pages

  Harrow, Alison ^a   Dryden, Ruth ^b   McCowan, Colin ^c   Radley, Andrew ^d   Parsons, Mark ^e   Thompson, Alastair M ^f   Wells, Mary ^g  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b Brunswick House   (United Kingdom)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

^d King's Cross Hospital   (United Kingdom)

^e NINEWELLS HOSPITAL   (United Kingdom)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^g UNIVERSITY OF STIRLING   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; LETROZOLE; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; AROMATASE INHIBITOR; NITRILE; TRIAZOLE DERIVATIVE;

ADULT; AGED; ARTHRALGIA; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; DOCTOR PATIENT RELATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MONITORING; FATIGUE; FEMALE; FOLLOW UP; HAIR LOSS; HEALTH BELIEF; HEALTH CARE PERSONNEL; HOT FLUSH; HUMAN; INSOMNIA; LIBIDO DISORDER; MAJOR CLINICAL STUDY; MEDICATION COMPLIANCE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; NAUSEA; NIGHT SWEAT; OSTEOGENESIS IMPERFECTA; PATIENT COMPLIANCE; PERSONAL EXPERIENCE; PRESCRIPTION; QUALITATIVE RESEARCH; QUALITY OF LIFE; REASSURANCE; REINFORCEMENT; SELF CARE; SIDE EFFECT; SUICIDAL IDEATION; VAGINAL DRYNESS; WEIGHT GAIN; ADJUVANT CHEMOTHERAPY; ATTITUDE TO HEALTH; BREAST NEOPLASMS; CLINICAL TRIAL; MULTICENTER STUDY;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; ATTITUDE TO HEALTH; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; MEDICATION ADHERENCE; MIDDLE AGED; NITRILES; QUALITATIVE RESEARCH; QUALITY OF LIFE; TAMOXIFEN; TRIAZOLES;

EID: 84903118223     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2014-005285     Document Type: Article

References (60)

1. McCowan C, Thompson AM. The importance of nonpharmacogenetic factors in endocrine therapy. Pharmacogenomics 2012;13:721-8.
2. Dunnwald L, Rossing M, Li C. Hormone receptor status, tumour characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Res 2007;9:R6.
3. Gray R. 10 years of tamoxifen better than 5 in reducing breast cancer recurrence and death. Annual Meeting of the American Society of Clinical Oncology, 2013.
4. Dowsett M, Cuzick J, Ingle J, et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 2010;28:509-18.
5. Smith IE, Arnedos M. The evolution of adjuvant endocrine therapy: developments since St Gallen. Breast 2007;16:54-9.
6. Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 2013;381:805-16.
7. Goss PE, Ingle JN, Martino S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J National Cancer Inst 2005;97:1262-71. (Pubitemid 41535367)
8. NICE NIfHaCE. Familial breast cancer. Classification and care of people at risk of familial breast cancer and related risks in people with a family history of breast cancer. NICE Clinical Guideline 164, 2013.
9. Cuzick J, Sestak I, Forbes JF, et al. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet 2014:383:1041-8. http://www.sciencedirect.com/science/article/pii/S0140673613622928
10. Barron TI, Connolly R, Bennett K, et al. Early discontinuation of tamoxifen: a lesson for oncologists. Cancer 2007;109:832-9. (Pubitemid 46333524)
11. Hershman D, Kushi L, Shao T, et al. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol 2010;28:4120-8.
12. Ma AM, Barone J, Wallis AE, et al. Noncompliance with adjuvant radiation, chemotherapy, or hormonal therapy in breast cancer. Am J Surg 2008;196:500-4.
13. Makubate B, Donnan P, Dewar JA, et al. Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality. Br J Cancer 2013;108:1515-24.
14. McCowan C, Shearer J, Donnan P, et al. Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer. Br J Cancer 2008;99:1763-8.
15. McCowan C, Wang S, Thompson A, et al. The value of high adherence to tamoxifen in women with breast cancer: a community-based cohort study. Br J Cancer 2013;109:1172-80.
16. Narod S. Compliance with tamoxifen in women with breast cancer and a BRCA1 or BRCA2 mutation. J Clin Oncol 2010;28:e698-9.
17. Owusu C, Buist D, Field T, et al. Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer. J Clin Oncol 2008;26:549-55. (Pubitemid 351264347)
18. van Herk-Sukel M, van de Poll-Franse L, Voogd A, et al. Half of breast cancer patients discontinue tamoxifen and any endocrine treatment before the end of the recommended treatment period of 5 years: a population-based analysis. Breast Cancer Res Treat 2010;122:843-51.
19. Dezentjé V, van Blijderveen N, Gelderblom H, et al. Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer. J Clin Oncol 2010;28:2423-9.
20. Hershman D, Shao T, Kushi L, et al. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat 2011;126:529-37.
21. Partridge AH, Wang PS, Winer EP, et al . Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 2003;21:602-6. (Pubitemid 46621892)
22. Garreau J, Delemelena T, Walts D, et al . Side effects of aromatase inhibitors versus tamoxifen: the patient's perspective. Am J Surg 2006;192:496-8. (Pubitemid 44362983)
23. Howell A, Cuzick J, Baum M, et al. Results of the ATAC (arimidex, tamoxifen, alone or in combination) trial after 5 years' adjuvant treatment for breast cancer. Lancet 2005;365:60-2.
24. Gibson LJ, Dawson CK, Lawrence DH, et al. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women. Cochrane Database Syst Rev 2007;7(4):CD003370.
25. Pelligrini I, Sarradon-Eck A, Soossan PB. Women's perceptions and experience of adjuvant tamoxifen therapy accounts for their adherence: breast cancer patients' point of view. Psychooncology 2010;19:472-9.
26. Stewart DE, Cheung AM, Duff S, et al . Attributions of cause in recurrence in long-term breast cancer survivors. Psychooncology 2001;10:179-83.
27. Murphy C, Bartholomew L, Carpentier M, et al. Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. Breast Cancer Res Treat 2012;134:459-78.
28. Dunbar-Jacob J, Mortimer-Stephens MK. Treatment adherence in chronic disease. J Clin Epidemiol 2001;54:S57-60. (Pubitemid 34013691)
29. Demissie S, Silliman RA, Lash TL. Adjuvant tamoxifen: predictors of use, side effects, and discontinuation in older women. J Clin Oncol 2001;19:322-8. (Pubitemid 32112842)
30. Lash TL, Fox MP, Westrup JL, et al. Adherence to tamoxifen over the five-year course. Breast Cancer Res Treat 2006;99:215-20. (Pubitemid 44268270)
31. Mao JJ, Chung A, Benton A, et al. Online discussion of drug side effects and discontinuation among breast cancer survivors. Pharmacoepidemiol Drug Saf 2013;22:256-62.
32. Cluze C, Rey D, Huiart L, et al. Adjuvant endocrine therapy with tamoxifen in young women with breast cancer: determinants of interruptions vary over time. Ann Oncol 2012;23:882-90.
33. Jansa M, Hernandez C, Vidal M, et al. Multidimensional analysis of treatment adherence in patients with multiple chronic conditions. A cross-sectional study in a tertiary hospital. Patient Educ Couns 2010;81:161-8.
34. Ritchie J, Spencer L. Qualitative data analysis for applied policy research. In: Bryman A, Burgess RG, eds. Analyzing qualitative data. London: Routledge, 1994:173-94.
35. NVivo qualitative data analysis software. Program (10 version) 2012.
36. Horne R, Weinman J. Patients' beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J Psychosom Res 1999;47:555-67. (Pubitemid 30029305)
37. Sabnis GJ, Macedo LF, Goloubeva O, et al. Stopping treatment can reverse acquired resistance to letrozole. Cancer Res 2008;68:4518-24.
38. Wengstrom Y, Aapro M, di Priolo S, et al. Patients' knowledge and experience of adjuvant endocrine therapy for early breast cancer. Breast 2007;16:462-8. (Pubitemid 47500032)
39. Fink AK, Gurwitz J, Rakowski W, et al. Patients beliefs and tamoxifen discontinuance in older women with oestrogen receptor positive breast cancer. J Clin Oncol 2004;22:3309-15. (Pubitemid 41103687)
40. Leventhal H, Brissette I, Leventhal EA. The common-sense model of self-regulation of health and illness. In: Cameron LD, Leventhal H, eds. The self-regulation of health and illness behaviour. London: Routledge, 2003:42-65.
41. Clifford S, Barbera N, Horne R. Understanding different beliefs held by adherers, unintentional nonadherers, and intentional nonadherers: application of the necessity-concerns framework. J Psychosom Res 2008;64:41-6. (Pubitemid 350297299)
42. Kreps GL, Villagran MM, Zhao X, et al. Development and validation of motivational messages to improve prescription medication adherence for patients with chronic health problems. Patient Educ Couns 2011;83:375-81.
43. Horne R, Weinman J, Hankins M. The beliefs about medicines questionnaire: the development and evaluation of a new method for assessing the cognitive representation of medication. Psychol Health 1999;14:1-24.
44. Schuz B, Marx C, Wurm S, et al. Medication beliefs predict medication adherence in older adults with multiple illnesses. J Psychosom Res 2011;70:179-87.
45. Carpenter DM, DeVellis RF, Fisher EB, et al. The effect of conflicting medication information and physician support on medication adherence for chronically ill patients. Patient Educ Couns 2010;81:169-76.
46. Kahn KL, Schneider EC, Malin JL, et al. Patient centred experiences in breast cancer. Predicting long-term adherence to tamoxifen use. Med Care 2007;45:431-9.
47. Albert US, Zemlin C, Hadji P, et al. The impact of breast care nurses on patients' satisfaction, understanding of the disease, and adherence to adjuvant endocrine therapy. Breast Care 2011;6:221-6.
48. Macmillan Cancer Support. Throwing light on the consequences of cancer and its treatment, 2013.
49. Güth U, Myrick M, Kilic N, et al. Compliance and persistence of endocrine adjuvant breast cancer therapy. Breast Cancer Res Treat 2012;131:491-9.
50. Hudson S, Miller S, Hemler J, et al. Adult cancer survivors discuss follow-up in primary care: 'Not What I Want, But Maybe What INeed'. Ann Fam Med 2012;10:418-27.
51. NICE. National Institute for Health and Care Excellence. Early and locally advanced breast cancer, 2009.
52. Raynor DKT. Health literacy. BMJ 2012;344:e2188.
53. Dixon A, LeGrand J, Henderson J, et al. Is the British National Health Service equitable? The evidence on socioeconomic differences in utilization. J Health Services Res Policy 2007;12:104-9. (Pubitemid 46733213)
54. Kaczorowski J, Chambers LW, Dolovich L, et al. Improving cardiovascular health at population level:39 community cluster randomised trial of cardiovascular health awareness programme (CHAP). BMJ 2011;342:d442.
55. Wells M. Hidden aspects of radiotherapy to the head and neck: a qualitative study of patients on completion of treatment. J Adv Nurs 1998;28:840-8. (Pubitemid 128451625)
56. Basch E, Abernethy AP. Supporting clinical practice decisions with real-time patient-reported outcomes. J Clin Oncol 2011:954-6.
57. Macmillan Cancer Support. After cancer treatment: a guide for professionals, 2013.
58. Fenlon DR, Corner JL, Haviland J. Menopausal hot flushes after breast cancer. Eur J Cancer Care 2009;18:140-8.
59. Cavanagh S, Chadwick K. Health needs assessment: a practical guide. National Institute for Health and Clinical Excellence, 2005.
60. National Cancer Survivorship Initiative. The recovery package. Secondary The recovery package 2012. http://www.ncsi.org.uk/what-we-are-doing/the- recovery-package/